- /
- Supported exchanges
- / US
- / RNAC.NASDAQ
Cartesian Therapeutics Inc. (RNAC NASDAQ) stock market data APIs
Cartesian Therapeutics Inc. Financial Data Overview
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Cartesian Therapeutics Inc. (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Cartesian Therapeutics Inc. data using free add-ons & libraries
Get Cartesian Therapeutics Inc. Fundamental Data
Cartesian Therapeutics Inc. Fundamental data includes:
- Net Revenue: 1 775 K
- EBITDA: -88 897 000
- Earnings Per Share: -5
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Cartesian Therapeutics Inc. Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-04-30
- EPS/Forecast: -0.7
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cartesian Therapeutics Inc. News
New
New Strong Sell Stocks for July 1st
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Caesars Entertainment, Inc. CZR is a gaming and hospitality company. The Zacks Consensus Estimate for its current year earni...
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?
Kiniksa Pharmaceuticals International, plc (KNSA) shares soared 5.4% in the last trading session to close at $62.41. The move was backed by solid volume with far more shares changing hands than in a n...
Cartesian Therapeutics Announces New Employment Inducement Grant
FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune ...
Top Biotech Gainers: RGNT Walks The Talk, ELOX Returns To Relevance, ALHC Rallies, LRMR On Watch
(RTTNews) - Tuesday's top biotech gainers include Regentis, which provided an update on its single-step knee repair implant; Eloxx, after getting uplisted to the Nasdaq; Alignment Healthcare, followi...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.